Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Dr. Deniz Tasdemir is a Full Professor (W3) of Marine Natural Products Chemistry at GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel and serves as Director of the GEOMAR-Biotech center and Head of the Marine Natural Product Chemistry Research Unit. Her career spans institutions including the National University of Ireland Galway and UCL School of Pharmacy. PhD in Pharmacy, ETH Zurich (1997) Post-doctoral work, University of Utah (2001) Dr. Helmut Legerlotz Fellowship, University of Zurich (2002-2025) Her research focuses on marine chemical ecology , metabolomics , and bioprospecting for bioactive compounds from sponges, algae, and marine microbiomes. Recent work explores seagrass pathogen reduction, microbiome interactions, and aquafeed applications. Scientific awards include: Waters Award for Natural Products Innovation (2016) Egon Stahl Silver Medal (2005) Pierre Fabre Prize (2004) ETH Zurich Medal (1997) She leads collaborative projects on ocean sustainability and marine drug discovery, with editorial roles in Marine Drugs , Planta Medica , and Phytochemistry Letters .
Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.
Prof. Andreas Bausch holds the Heinz Nixdorf Endowed Chair of Cell Biophysics at the Technical University of Munich (TUM) within the TUM School of Natural Sciences . His research focuses on cellular biophysics , particularly the mechanical properties of cytoskeletal networks and self-organization mechanisms in biological systems, with applications in biomimetic materials and organoid modeling. Research Areas : Cytoskeletal mechanics, active matter systems, organoid morphogenesis, integrin signaling, synthetic cell models Techniques : Microrheology, in vitro reconstitution, microfluidics, advanced imaging His work has produced over 100 publications in Nature, Science, PNAS , and Physical Review Letters , with recent emphasis on pancreatic cancer organoids and artificial cell membranes . Key findings include: Discovery of topological excitations governing endothelial cell ordering Elucidation of PIP2/PIP3 regulation in integrin phase separation Development of 3D patterned organoid systems for drug screening Major awards include: ERC Synergy Grant (2018) ERC Advanced Grant (2012) ERC Starting Grant (2011) Berlin-Brandenburg Academy of Sciences Prize (2014) He serves as founding director of the Center for Functional Protein Assemblies (CPA) since 2015 and teaches biomechanics , biophysics , and protein assemblies at TUM. His lab investigates both fundamental biophysical principles and their medical applications in cancer and cardiovascular systems.
Ying Ge is a Professor at the University of Wisconsin–Madison, jointly appointed in the Department of Cell and Regenerative Biology and the Department of Chemistry. Her research integrates chemistry, biology, and medicine, focusing on advanced mass spectrometry-based proteomic and metabolomic technologies to address cardiovascular diseases. Education: B.S., Peking University (1997) Ph.D., Cornell University (2002) Ying Ge's work centers on developing ultra high-resolution mass spectrometry platforms for top-down proteomics and metabolomics, applied to systems biology studies of heart failure and regenerative medicine. Key projects include myofilament protein modification mapping, stem cell therapy evaluation, and biomarker discovery for cardiac conditions. The 15 most recent articles highlight her lab's methodological innovations (e.g., photocleavable surfactants, native mass spectrometry) and biological discoveries in AMPK structural heterogeneity, RBM20-mediated cardiotoxicity, and sarcomere-metabolism cross-talk during regeneration. These publications span proteomics, metabolomics, structural biology, and clinical applications.
Dr. Timur Alexander Yorgan is a prominent researcher at the Department of Osteology and Biomechanics at University Medical Center Hamburg-Eppendorf (UKE). Holding a Dr. rer. nat. degree, he has established himself as a leading figure in bone biology with over 60 publications spanning from 2013 to 2025. His research is deeply integrated with key institutional research areas including the Hamburg Center of Neuroscience and immunology research networks at UKE. Dr. Yorgan's research focuses on skeletal development, bone remodeling, and genetic bone disorders, with particular emphasis on Wnt signaling pathways and their role in bone homeostasis. His work spans multiple approaches from molecular genetics to translational studies, investigating osteoblast and osteocyte biology, genetic mechanisms underlying disorders like osteogenesis imperfecta, and the effects of various mutations on skeletal integrity. Recent research has expanded into the gut-bone axis, mechanobiology of bone cells, and neuro-immune interactions affecting bone metabolism. Analysis of Dr. Yorgan's publication record reveals a consistent trajectory of high-impact research in bone biology. His work increasingly explores interdisciplinary connections between bone metabolism and other physiological systems, with growing emphasis on translational approaches for therapeutic interventions. The research demonstrates sophisticated use of mouse models and molecular techniques to unravel complex bone disorders and identify potential treatment targets. Dr. Yorgan appears to be actively involved in collaborative research across multiple institutions, as evidenced by his extensive publication record with numerous co-authors from various departments and institutions. His work is frequently published in high-impact journals including Journal of Bone and Mineral Research, Nature Communications, and Bone Research. The Department of Osteology and Biomechanics at UKE, where Dr. Yorgan is based, is part of a vibrant research ecosystem that includes the Hamburg Center of Neuroscience and other key research networks focusing on immunology, oncology, and cardiovascular research. This collaborative environment enables interdisciplinary approaches to understanding skeletal disorders and developing novel therapeutic strategies.
Sudin Bhattacharya is an Associate Professor at the BioMolecular Science Gateway, Michigan State University, with affiliations in the Genetics & Genome Sciences Program and Cell & Molecular Biology Program. His research bridges computational biology and toxicology to understand complex biological systems. Email: sbhattac@msu.edu Research Interests Dr. Bhattacharya specializes in systems toxicology, focusing on computational modeling of gene regulatory networks, single-cell transcriptomics, and molecular dynamics in response to environmental toxicants. His work examines how chemical exposures disrupt cellular pathways and contribute to disease mechanisms. Article Trends His recent publications emphasize: Single-cell and single-nucleus RNA sequencing for toxicological profiling Computational models of circadian rhythms and intercellular communication Dose-dependent responses to environmental chemicals like TCDD and heavy metals Mechanistic studies of adipose tissue remodeling and hypertension Applications of machine learning in chemical risk assessment Integrative approaches to liver metabolism and disease modeling Scientific Contributions Dr. Bhattacharya has pioneered multiscale modeling of biological systems, particularly in hepatic and vascular contexts. His work on the aryl hydrocarbon receptor and PPARα signaling networks has advanced predictive toxicology frameworks.
Suzanne Estaphan is a Senior Lecturer in Medical Science (Physiology and Clinical Pharmacology) at the Australian National University (ANU) School of Medicine and Psychology . She holds qualifications including a Doctorate of Physiology (2015) , MSc in Physiology (2012) , MBBCh (2005) , and Basic Certificate in Medical Education (2018) . Her academic roles span curriculum development, admissions, and assessment committees in the ANU Medical School. Senior Lecturer, ANU (2023–present) Academic Editor, PLOS ONE (2024–present) Review Editor, Frontiers in Physiology (2023–present) Dr. Estaphan's research bridges oxidative stress and inflammation in disease pathology with medical education innovation . Her work explores antioxidant interventions for organ damage and investigates AI/virtual reality applications in education. Recent projects include studying sleep dysfunction in eating disorders and diabetes medication effects on exercise capacity . Between 2023–2025, her 15 most recent publications span oxidative stress , medical education , and molecular pathophysiology . Themes include homeostasis , clinical reasoning , and metabolic disorders , with subfields like MMP-9 biology , pancreatic injury , and VR-based hypoxia training . Scientific accolades include the American Physiological Society Travel Award (2017) and recognition as Senior Fellow of the Higher Education Academy (2023) . She mentors medical students, contributes to national physiology curriculum consensus projects, and has secured approximately $200,000 in research funding .
Bertrand Coste is a CNRS Researcher at the Cognitive Neuroscience Laboratory (Aix-Marseille University/CNRS), specializing in mechanosensation and ion channel biology. He developed pioneering techniques to study mechanically activated ion channels, notably discovering the PIEZO1 and PIEZO2 channels with Prof. Ardem Patapoutian, which contributed to the 2021 Nobel Prize in Physiology or Medicine. His current work focuses on pain perception mechanisms and cardiovascular functions of PIEZO channels. Education: Completed his PhD at the Laboratoire de neurophysiologie cellulaire in Marseille, followed by postdoctoral research at the Scripps Research Institute, CA (2007–2012). Research Interests: Molecular basis of mechanosensation, mechanosensitive ion channels (PIEZO family), pain signaling, and cardiovascular physiology. His studies bridge molecular neurobiology with clinical applications in chronic pain management and genetic disorders linked to mechanosensory defects. Publications highlight advancements in PIEZO channel structure-function relationships, their roles in sensory perception, and contributions to pathologies like hereditary stomatocytosis and arthrogryposis. His work integrates genetics, cell biology, and biophysics to decode mechanical signaling pathways. Received the Brixham Foundation 2022 Award (Fondation pour la Recherche Médicale) for research on pain mechanisms. Collaborates with interdisciplinary teams at the CNRS and Aix-Marseille University, advancing translational neuroscience initiatives.
Jonathan Little is a Professor at the University of British Columbia Okanagan , affiliated with the Faculty of Health and Social Development and School of Health and Exercise Sciences . He leads the Exercise Metabolism and Inflammation Laboratory (EMIL) , focusing on the intersection of exercise physiology, nutrition, and metabolic disorders. Hons B. Kin – McMaster University, 2005 M.Sc. – University of Saskatchewan, 2007 Ph.D. – McMaster University, 2010 Postdoctoral Fellowship – UBC, 2010-2012 His research investigates how metabolic disruptions in type 2 diabetes affect cellular inflammation and how exercise/nutritional strategies can mitigate these effects. Key areas include high-intensity interval training (HIIT) , nutritional ketosis , and immunometabolic responses . EMIL combines human clinical trials with cellular/molecular experiments, utilizing advanced tools like flow cytometry and metabolic carts. His recent publications emphasize exercise snacks (short, frequent workouts), ketone supplements , and fasting protocols for managing diabetes and obesity. He has received prestigious awards like the Killam Accelerator Fellowship and CIHR New Investigator Award . Killam Accelerator Research Fellowship (2021-2023) Canadian Society for Exercise Physiology Young Investigator Award (2020) UBC Killam Research Fellowship (2018) Michael Smith Foundation for Health Research Scholar (2018-2023) American College of Sports Medicine New Investigator Award (2016) CIHR New Investigator Salary Award (2015-2020) He supervises graduate students in HMKN 313 – Exercise Metabolism and mentors through the HMKN 499 Research Practicum . His lab (EMIL) collaborates with institutions like the BC Diabetes Research Network and serves as an Associate Editor for Applied Physiology, Nutrition and Metabolism .
Professor Sir Peter Barnes is a leading figure in respiratory science at Imperial College London's National Heart and Lung Institute (NHLI) . As Professor of Thoracic Medicine , his work focuses on Asthma, COPD, and cellular senescence in lung disease , with over four decades of contributions to understanding inflammatory pathways and therapeutic innovations. Research Interests Mechanisms of chronic airway inflammation in Asthma and COPD Cellular senescence in lung aging and disease progression MicroRNA transfer via extracellular vesicles in COPD pathogenesis Targeted drug delivery for respiratory conditions Global health implications of lung disease Recent Publications highlight trends in: MicroRNA regulation of senescence and inflammation Extracellular vesicle dynamics in lung disease Biologics and corticosteroid efficacy in respiratory conditions Environmental factors influencing COPD and asthma Scientific Recognition Knighthood (2023) for services to respiratory science Fellow of the Royal Society (FRS) and Academy of Medical Sciences (FMedSci) Collaborative Leadership at NHLI has mentored numerous postdocs and researchers. His work intersects with global initiatives like GOLD (Global Initiative for COPD) , influencing clinical guidelines and public health policy.
Dr. Praveen Bhugra is a Senior Lecturer in Pharmacology at the University of Sunderland , where he has taught graduate courses including MPharm since 2006. His expertise spans cardiovascular, central nervous system, and autonomic pharmacology with a focus on receptor regulation in disease states. MSc (Pharmacology) from The Maharaja Sayajirao University of Baroda, India PhD (Medical Pharmacology) from Sardar Patel University, India His research integrates experimental pharmacology, molecular techniques (cell culture, calcium flux analysis), and biochemical approaches. Notably, he supervised PhD candidate Thomas Cherian (awarded 2014) on ureteral motility mechanisms. He authored the widely used textbook MCQs in Pharmacology (2000) and contributed to cardiovascular research during a 2000-2001 Visiting Scientist fellowship at the Institute of Cardiovascular Research, University of Manitoba, Canada. Recent publications (2015-2001) emphasize neurodegenerative pharmacology , hypertension mechanisms , and lipid mediator roles in cardiovascular disease . His work has been recognized with awards from the Indian Pharmacological Society and the International Society for Heart Research. Jaypur Prize (1985-86) C.L. Malhotra Research Prize (1994) Ahmedabad Branch Prizes (1996, 2001) National Academy of Medical Sciences Membership (2000) He has also contributed to public health research on probiotics in Clostridium difficile infection and participated in systematic reviews of substance abuse patterns in youth. Contact: praveen.bhugra@sunderland.ac.uk
